Dendritic Cell-targeted Vaccines--hope or Hype?

Overview

Journal Nat Rev Immunol

Specialty Allergy & Immunology

Date 2014 Sep 6

PMID 25190285

Citations 112

Authors

Wolfgang Kastenmuller

Kathrin Kastenmuller

Christian Kurts

Robert A Seder

Affiliations

Soon will be listed here.

Abstract

The development of an effective vaccine that elicits a strong and durable T cell response against intracellular pathogens and cancer is a challenge. One strategy to enhance the effectiveness of vaccination is by targeting dendritic cells (DCs). In this Opinion article, we discuss existing DC-targeting approaches that induce adaptive immunity. We highlight the crucial issues that need to be addressed to move the field forward and discuss whether targeting DCs could be better than current vaccine approaches.

Citing Articles

CD40 Ligand Potentiates Immunogenecity of Subunit Vaccine Candidate in a Murine Model.

Shu J, Li G, Shu J, Feng H, He Y Curr Issues Mol Biol. 2025; 47(1).

PMID: 39852152 PMC: 11763752. DOI: 10.3390/cimb47010037.

Enhancing cell-mediated immunity through dendritic cell activation: the role of Tri-GalNAc-modified PLGA-PEG nanoparticles encapsulating SR717.

Gong Y, Jia H, Dang W, Zhou T, He P, Wang X Front Immunol. 2025; 15:1490003.

PMID: 39763671 PMC: 11701044. DOI: 10.3389/fimmu.2024.1490003.

Nonviral targeted mRNA delivery: principles, progresses, and challenges.

He X, Li G, Huang L, Shi H, Zhong S, Zhao S MedComm (2020). 2025; 6(1):e70035.

PMID: 39760110 PMC: 11695212. DOI: 10.1002/mco2.70035.

Better, Faster, Stronger: Accelerating mRNA-Based Immunotherapies With Nanocarriers.

Carvalho H, Fidalgo T, Acurcio R, Matos A, Satchi-Fainaro R, Florindo H Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024; 16(6):e2017.

PMID: 39537215 PMC: 11655444. DOI: 10.1002/wnan.2017.

Advanced technologies for the development of infectious disease vaccines.

Gupta A, Rudra A, Reed K, Langer R, Anderson D Nat Rev Drug Discov. 2024; 23(12):914-938.

PMID: 39433939 DOI: 10.1038/s41573-024-01041-z.

References

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

Pardoll D . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4):252-64. PMC: 4856023. DOI: 10.1038/nrc3239. View

Li D, Romain G, Flamar A, Duluc D, Dullaers M, Li X . Targeting self- and foreign antigens to dendritic cells via DC-ASGPR generates IL-10-producing suppressive CD4+ T cells. J Exp Med. 2012; 209(1):109-21. PMC: 3260876. DOI: 10.1084/jem.20110399. View

Kreutz M, Tacken P, Figdor C . Targeting dendritic cells--why bother?. Blood. 2013; 121(15):2836-44. DOI: 10.1182/blood-2012-09-452078. View

Palucka A, Ueno H, Connolly J, Kerneis-Norvell F, Blanck J, Johnston D . Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother. 2006; 29(5):545-57. DOI: 10.1097/01.cji.0000211309.90621.8b. View

Heit A, Gebhardt F, Lahl K, Neuenhahn M, Schmitz F, Anderl F . Circumvention of regulatory CD4(+) T cell activity during cross-priming strongly enhances T cell-mediated immunity. Eur J Immunol. 2008; 38(6):1585-97. DOI: 10.1002/eji.200737966. View

Carayanniotis G, Barber B . Adjuvant-free IgG responses induced with antigen coupled to antibodies against class II MHC. Nature. 1987; 327(6117):59-61. DOI: 10.1038/327059a0. View

van Montfoort N, Mangsbo S, Camps M, van Maren W, Verhaart I, Waisman A . Circulating specific antibodies enhance systemic cross-priming by delivery of complexed antigen to dendritic cells in vivo. Eur J Immunol. 2012; 42(3):598-606. DOI: 10.1002/eji.201141613. View

Heit A, Maurer T, Hochrein H, Bauer S, Huster K, Busch D . Cutting edge: Toll-like receptor 9 expression is not required for CpG DNA-aided cross-presentation of DNA-conjugated antigens but essential for cross-priming of CD8 T cells. J Immunol. 2003; 170(6):2802-5. DOI: 10.4049/jimmunol.170.6.2802. View

10.

Dong H, Stanek O, Salvador F, Langer U, Morillon E, Ung C . Induction of protective immunity against Mycobacterium tuberculosis by delivery of ESX antigens into airway dendritic cells. Mucosal Immunol. 2012; 6(3):522-34. DOI: 10.1038/mi.2012.92. View

11.

Sancho D, Mourao-Sa D, Joffre O, Schulz O, Rogers N, Pennington D . Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J Clin Invest. 2008; 118(6):2098-110. PMC: 2391066. DOI: 10.1172/JCI34584. View

12.

Chatterjee B, Smed-Sorensen A, Cohn L, Chalouni C, Vandlen R, Lee B . Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells. Blood. 2012; 120(10):2011-20. DOI: 10.1182/blood-2012-01-402370. View

13.

Hamzah J, Jugold M, Kiessling F, Rigby P, Manzur M, Marti H . Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature. 2008; 453(7193):410-4. DOI: 10.1038/nature06868. View

14.

Horner A, Datta S, Takabayashi K, Belyakov I, Hayashi T, Cinman N . Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites. J Immunol. 2001; 167(3):1584-91. DOI: 10.4049/jimmunol.167.3.1584. View

15.

Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. PMC: 3563263. DOI: 10.1056/NEJMoa1200694. View

16.

Palucka K, Banchereau J . Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012; 12(4):265-77. PMC: 3433802. DOI: 10.1038/nrc3258. View

17.

Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S . Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol. 2002; 20:621-67. DOI: 10.1146/annurev.immunol.20.100301.064828. View

18.

Wang B, Henao-Tamayo M, Harton M, Ordway D, Shanley C, Basaraba R . A Toll-like receptor-2-directed fusion protein vaccine against tuberculosis. Clin Vaccine Immunol. 2007; 14(7):902-6. PMC: 1951063. DOI: 10.1128/CVI.00077-07. View

19.

Bachem A, Guttler S, Hartung E, Ebstein F, Schaefer M, Tannert A . Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells. J Exp Med. 2010; 207(6):1273-81. PMC: 2882837. DOI: 10.1084/jem.20100348. View

20.

Poulin L, Salio M, Griessinger E, Anjos-Afonso F, Craciun L, Chen J . Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp Med. 2010; 207(6):1261-71. PMC: 2882845. DOI: 10.1084/jem.20092618. View